{
    "clinical_study": {
        "@rank": "161417", 
        "arm_group": {
            "arm_group_label": "Omacetaxine :Consolidation /Maintenance", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of omacetaxine for\n      consolidation in patients age 60 and older with Myelogenous Leukemia(AML)in first complete\n      remission following induction with cytarabine and daunorubicin. And to assess the safety and\n      tolerability of omacetaxine for maintenance in patients age 60 and older with acute AML in\n      first complete remission following 3 consolidation courses with omacetaxine."
        }, 
        "brief_title": "Omacetaxine for Consolidation and Maintenance", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myelogenous Leukemia (AML)", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of AML including de novo, secondary, or with an antecedent hematologic\n             disorder [AHD] according to the World Health Organization (WHO) criteria[26]  in CR1\n             after induction chemotherapy\n\n          2. Age > 60 years.\n\n          3. Provide signed written informed consent.\n\n          4. Be able to comply with study procedures and follow-up examinations.\n\n          5. Be non-fertile or agree to use birth control during the study through the end of last\n             treatment visit.\n\n          6. Adequate renal and hepatic function:\n\n               1. Total bilirubin < 1.5 x institutional Upper Limit of Normal (ULN); and\n\n               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN;\n                  and\n\n               3. Serum creatinine < 1.2 times the upper limit of normal.\n\n          7. ECOG performance < 2\n\n          8. Patients with a history of carcinoma in remission, on no therapy or on hormonal\n             therapy for the adjuvant treatment of breast carcinoma or prostate carcinoma are\n             included in the study.\n\n          9. Any cytotoxic chemotherapy to treat carcinoma or major surgery must have concluded\n             within > 4 weeks of enrollment onto this study.\n\n             -\n\n        Exclusion Criteria:\n\n          1. Age <60\n\n          2. Patient not in CR after induction chemotherapy\n\n          3. Prior treatment with omacetaxine\n\n          4. Relapsed or refractory AML.\n\n          5. Investigational agent received within 30 days prior to the first dose of study drug.\n             If received any investigational agent prior to this time point, drug-related\n             toxicities must have recovered to Grade 2 or less prior to first dose of study drug.\n\n          6. Psychiatric disorders that would interfere with consent, study participation, or\n             follow-up.\n\n          7. Systemic fungal, bacterial, viral, or other infection not controlled (defined as\n             exhibiting ongoing signs/symptoms related to the infection and without improvement,\n             despite appropriate antibiotics or other treatment).\n\n          8. Any other severe concurrent disease, or have a history of serious organ dysfunction\n             or disease involving the heart, kidney, liver, or other organ system that may place\n             the patient at undue risk to undergo the proposed therapy.\n\n          9. No social support and inability to self-administer subcutaneous injections.\n\n         10. Active carcinoma requiring systemic chemotherapy or radiation therapy.\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873495", 
            "org_study_id": "IRB00057844", 
            "secondary_id": "Winship2176-11"
        }, 
        "intervention": {
            "arm_group_label": "Omacetaxine :Consolidation /Maintenance", 
            "description": "Omacetaxine 1.25 mg/m\u00b2 sub-cutaneously twice daily for 10 consecutive days every 28 (\u00b13) days for 3 cycles.\nPatients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25mg/m2 twice daily for 5 days, every 28 days for up to 6 cycles", 
            "intervention_name": "Omacetaxine", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "contact": {
                "email": "MARELLA@emory.edu", 
                "last_name": "Marth Arellano, MD", 
                "phone": "404-778-1900"
            }, 
            "facility": {
                "address": {
                    "city": "Atlanta", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30322"
                }, 
                "name": "Emory University Winship Cancer Institute"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Omacetaxine for Consolidation and Maintenance in Patients Age 60 and Older With AML in First Remission: a Pilot Study", 
        "overall_contact": {
            "email": "marella@emory.edu", 
            "last_name": "Martha L Arellano, MD", 
            "phone": "1-888-946-7447"
        }, 
        "overall_contact_backup": {
            "email": "hkhoury@emory.edu", 
            "last_name": "Hanna Jean Khoury, MD", 
            "phone": "1-888-946-7447"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Disease status will be assessed by a bone marrow aspirate and biopsy prior to each of 3 consolidation cycles (to ensure that patients are still in remission)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "measure": "Bone marrow biopsy and aspirate will be obtained", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Bone marrow aspirate to confirm continuous remission will be obtained before starting maintenance and at 3 and 6 months from the start of maintenance.", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Toxicities will be monitored by history, physical examination, and laboratory monitoring-during maintenance", 
                "safety_issue": "Yes", 
                "time_frame": "24 week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873495"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Emory University", 
            "investigator_full_name": "Martha Arellano", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Toxicities will be monitored by history, physical examination, and laboratory monitoring (CBC, serum chemistries to include renal and liver function tests) obtained weekly during consolidation and monthly during maintenance according to standard of care (Appendices C and D). Toxicity will be assessed according to the NCI Common Toxicity Criteria Version 4.0 (available at the NCI web site http://ctep.cancer.gov/reporting/ctc.html).", 
            "measure": "Toxicities will be monitored by history, physical examination, and laboratory monitoring-during consolidation", 
            "safety_issue": "Yes", 
            "time_frame": "12 week"
        }, 
        "source": "Emory University", 
        "sponsors": {
            "collaborator": {
                "agency": "Teva Pharmaceuticals USA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Emory University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}